RESUMEN
Liver X receptor (LXR), a member of the superfamily of nuclear receptors, plays an important role in the activation of transcription factors involved in cholesterol metabolism, glucose homeostasis inflammation and lipogenesis. It is shown that LXR agnoists have the potentiality to be used as drugs for the prevention and treatment of atherosclerosis, which is its best investigated therapeutic indication. There are many compounds being studied in preclinical evaluation and biological assay. This paper will review briefly the LXR agonists in recent years.
Asunto(s)
Animales , Humanos , Transportadoras de Casetes de Unión a ATP , Metabolismo , Aminas , Química , Farmacología , Aterosclerosis , Quimioterapia , Metabolismo , Bencimidazoles , Química , Farmacología , Colesterol , Farmacología , Glucosa , Farmacología , Metabolismo de los Lípidos , Lipogénesis , Receptores X del Hígado , Receptores Nucleares Huérfanos , Fisiología , Quinolinas , Química , Farmacología , Proteína 1 de Unión a los Elementos Reguladores de Esteroles , MetabolismoRESUMEN
Several new drug targets of anti-atherosclerosis, emerging in the recent years, such as PPAR agonists, cholesteryl ester transfer protein (CETP) inhibitors, infusion of apolipoprotein A-I (apoA-I), liver X receptor (LXR) activators and phospholipid transfer protein (PLTP) inhibitors etc were reviewed.